These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1423975)

  • 1. Subcutaneous heparin during coronary thrombolysis. Too little, too late.
    Delanty N; Fitzgerald DJ
    Circulation; 1992 Nov; 86(5):1636-8. PubMed ID: 1423975
    [No Abstract]   [Full Text] [Related]  

  • 2. Conjunctive heparin therapy. Limitations of subcutaneous administration.
    Goldhaber SZ
    Circulation; 1992 Nov; 86(5):1639-41. PubMed ID: 1423976
    [No Abstract]   [Full Text] [Related]  

  • 3. Principles and practice of coronary thrombolysis and conjunctive treatment.
    Sobel BE; Hirsh J
    Am J Cardiol; 1991 Aug; 68(4):382-8. PubMed ID: 1858680
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical examination of heparin-Ca in myocardial infarction patients.
    Páder K; Kerkovits G
    Ther Hung; 1990; 38(3):114-6. PubMed ID: 2284620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers.
    Kroon C; ten Hove WR; de Boer A; Kroon JM; van der Pol JM; Harthoorn-Lasthuizen EJ; Schoemaker HC; van der Meer FJ; Cohen AF
    Circulation; 1992 Nov; 86(5):1370-5. PubMed ID: 1423948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous enoxaparin following thrombolysis and intravenous unfractionated heparin in ST-elevation acute myocardial infarction: safety and efficacy of low vs full dose.
    Rubboli A; Gatti C; Spinolo L; Parollo R; Spitali G; Maresta A
    Minerva Cardioangiol; 2006 Feb; 54(1):131-7. PubMed ID: 16467747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction.
    Prins MH; Hirsh J
    Am J Cardiol; 1991 Jan; 67(3):3A-11A. PubMed ID: 1990783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction.
    Wang XK; Zhang Y; Yang CM; Wang Y; Liu GY
    Clin Drug Investig; 2006; 26(6):341-9. PubMed ID: 17163268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin modifies platelet count and function in patients who have undergone thrombolytic therapy for acute myocardial infarction.
    Balduini CL; Noris P; Bertolino G; Previtali M
    Thromb Haemost; 1993 May; 69(5):522-3. PubMed ID: 8322276
    [No Abstract]   [Full Text] [Related]  

  • 10. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction?
    Ridker PM; Hebert PR; Fuster V; Hennekens CH
    Lancet; 1993 Jun; 341(8860):1574-7. PubMed ID: 8099650
    [No Abstract]   [Full Text] [Related]  

  • 11. Thrombolysis after acute myocardial infarction. Who should be added to inclusion criteria?
    Figueredo VM; Amidon TM; Wolfe CL
    Postgrad Med; 1994 Dec; 96(8):30-4, 37-40. PubMed ID: 7991476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of thrombolysis in acute myocardial infarction. Part III. Optimalization of adjunctive therapy after thrombolytic therapy.
    Habib GB
    Chest; 1995 Mar; 107(3):809-16. PubMed ID: 7874958
    [No Abstract]   [Full Text] [Related]  

  • 13. [Aspirin and heparin in the fibrinolytic treatment of acute myocardial infarction].
    López Bescós L
    Rev Esp Cardiol; 1992; 45 Suppl 2():21-8. PubMed ID: 1475505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
    GUSTO investigators
    N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans.
    Gold HK; Garabedian HD; Dinsmore RE; Guerrero LJ; Cigarroa JE; Palacios IF; Leinbach RC
    Circulation; 1997 Apr; 95(7):1755-9. PubMed ID: 9107158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Heparin therapy in coronary disease].
    Gulba DC
    Dtsch Med Wochenschr; 1992 Jan; 117(1):35-6. PubMed ID: 1730197
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of heparin in coronary thrombolysis.
    Eisenberg PR
    Chest; 1992 Apr; 101(4 Suppl):131S-139S. PubMed ID: 1555478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate.
    Salvioni A; Perego GB; Marenzi G; Lauri G; Giraldi F; Grazi S; Guazzi MD
    Eur Heart J; 1996 Feb; 17(2):230-6. PubMed ID: 8732376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction].
    Zhang Y; Wang XK; Yang CM; Liu GY
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Jan; 24(1):81-4. PubMed ID: 14724106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.